These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31501370)

  • 1. [Examination of Actual Medical Material Cost and Cost Reduction Related to Exposure Prevention in the Preparation of Anticancer Drugs].
    Moriya A; Usami E; Hirose T; Takenaka S; Asano H; Okada K; Adachi S; Yoshimura T
    Gan To Kagaku Ryoho; 2019 Aug; 46(8):1281-1286. PubMed ID: 31501370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Verification of reduction in preparation time and cost of cyclophosphamide when using the closed-system drug transfer device].
    Ikeno Y; Arii D; Nakajima H; Murooka K; Nojima M; Kidokoro A
    Gan To Kagaku Ryoho; 2014 May; 41(5):611-5. PubMed ID: 24917007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Analysis of Using a Closed-System Transfer Device (CSTD) for Antineoplastic Drug preparation in a Malaysian Government-Funded Hospital.
    Chan HK; Lim YM
    Asian Pac J Cancer Prev; 2016 Nov; 17(11):4951-4957. PubMed ID: 28032722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of Increased Use of a Closed System Drug Transfer Device and Simplification of Personal Protective Equipment on the Cost of Medical Materials].
    Hashimoto H; Mukai S; Miyazaki M; Yamaguchi K; Murakami M
    Gan To Kagaku Ryoho; 2021 Jul; 48(7):927-931. PubMed ID: 34267030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques.
    Harrison BR; Peters BG; Bing MR
    Am J Health Syst Pharm; 2006 Sep; 63(18):1736-44. PubMed ID: 16960258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer drug waste minimization and cost-saving study by using a closed-system transfer device for chemotherapy compounding.
    Adade CA; Diop BB; Attjioui H; Cheikh A; Mefetah H; Bouatia M
    J Oncol Pharm Pract; 2022 Apr; 28(3):605-612. PubMed ID: 33847197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment time, ease of use and cost associated with use of Equashield™, PhaSeal
    Kicenuik K; Northrup N; Dawson A; Locke J; Villamil JA; Chretin J; Sfiligoi G; Clifford C; Rosenberg M; Hamilton T; Regan R; Parsons-Doherty M; Mallett C; Philibert J; Impellizeri J; Hofmeister E
    Vet Comp Oncol; 2017 Mar; 15(1):163-173. PubMed ID: 25864458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital.
    Matsuo K; Nomura H; Uchiyama M; Miyazaki M; Imakyure O
    BMC Health Serv Res; 2020 Nov; 20(1):1017. PubMed ID: 33167996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a simple compatibility inspection method using pressure in a BD PhaSeal™ system and hazardous drug vials.
    Ishimaru H; Tsuda Y; Kage H; Kawano T; Takayama S; Morimoto Y; Goto K; Watanabe K
    J Oncol Pharm Pract; 2021 Sep; 27(6):1321-1327. PubMed ID: 32854576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs).
    Sumikawa S; Yakushijin Y; Aogi K; Yano T; Hiroki ; Hashimoto ; Tsukui C; Noguchi T; Shiraishi T; Horikawa Y; Yasuoka Y; Tanaka A; Hidaka N; Tanaka M
    Sci Rep; 2022 Jan; 12(1):139. PubMed ID: 34996936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of studies examining microbial contamination of vials used for preparations done with closed-system drug transfer devices.
    Soubieux A; Tanguay C; Bussières JF
    Eur J Hosp Pharm; 2021 Mar; 28(2):65-70. PubMed ID: 33608432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing a protocol for the compatibilities of closed-system transfer devices with multiple chemotherapy drugs under simulated clinical conditions.
    Chiang SC; Shen M; Lin CC; Chang HP
    PLoS One; 2021; 16(9):e0257873. PubMed ID: 34582474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs.
    Bartel SB; Tyler TG; Power LA
    Am J Health Syst Pharm; 2018 Feb; 75(4):199-211. PubMed ID: 29339374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost savings realized by use of the PhaSeal(®) closed-system transfer device for preparation of antineoplastic agents.
    Edwards MS; Solimando DA; Grollman FR; Pang JL; Chasick AH; Hightman CM; Johnson AD; Mickens MG; Preston LM
    J Oncol Pharm Pract; 2013 Dec; 19(4):338-47. PubMed ID: 23975556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Safe Handling of Cancer Chemotherapy Drugs in Pharmacy(Preparations, Transport and Safe Deposit)].
    Nomura H
    Gan To Kagaku Ryoho; 2017 Jul; 44(7):554-557. PubMed ID: 28790255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of Contamination with Antibiotics on Surfaces and in Environmental Air in Three European Hospitals Following Implementation of a Closed-System Drug Transfer Device.
    Sessink PJM; Nyulasi T; Haraldsson ELM; Rebic B
    Ann Work Expo Health; 2019 Apr; 63(4):459-467. PubMed ID: 30852616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of unintended volume loss of six closed system transfer devices.
    Kulju S; McIntosh BA; Fuller HJ; Arnold T; Gunnar W
    J Oncol Pharm Pract; 2020 Jul; 26(5):1134-1140. PubMed ID: 31775580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of Holdup Volume and Transient Contact Compatibility of Closed System Transfer Devices for a Reconstituted Lyophilized Drug Product.
    Kagdi R; Le K; Doucet D; Ludlow J; Rinella JV
    J Pharm Sci; 2020 Nov; 109(11):3504-3511. PubMed ID: 32771346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Economic Loss of Remaining Contents in Molecular Target Drug Preparation and the Simulation for Cost Saving].
    Usami E; Kimura M; Fukuoka T; Okada K; Yoshimura T
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):743-7. PubMed ID: 27306812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing a flowchart to evaluate the use of Closed System Drug-Transfer Devices with monoclonal antibodies: Focus on the clinical trial setting.
    Simal I; Bauters T; Paepens C; Clottens N; Ramaut P; Kestens E
    J Oncol Pharm Pract; 2023 Dec; 29(8):2014-2022. PubMed ID: 37680124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.